NUSO Announces Global Partnership with Zoom to Strengthen Enterprise Communication and Collaboration
7.10.2025 14:30:00 CEST | Business Wire | Press Release
NUSO, a global provider of cloud communications, today announced the expansion of its partnership with Zoom Communications, Inc. Building on its existing support for Zoom Cloud Peering in the Americas and EMEA, NUSO will now serve as a global partner for Zoom Phone and Zoom Contact Center licenses. This step extends a proven relationship and brings customers a direct path to combine Zoom’s platform with NUSO’s global network and compliance-ready services.
“Our partnership with Zoom now goes beyond Cloud Peering,” said Matt Siemens, CEO of NUSO. “We are combining Zoom’s proven collaboration tools with NUSO’s global delivery model and our AI and compliance solutions like NUSO Connect Recorder. This partnership delivers real outcomes for partners and customers through choice, international scale, compliance, and resiliency.”
This expanded partnership allows enterprises and partners to better:
- Drive business outcomes – By combining collaboration, telephony, and compliance services, enterprises reduce complexity, accelerate deployments, and improve customer engagement worldwide.
- Strengthen compliance and security – NUSO Connect Recorder supports regulatory requirements including GDPR, PCI DSS, and MiFID II, while providing transcription, analysis, and encryption.
- Gain resiliency – Resiliency from the ground up to maximize business continuity with features like NUSOflex
- Scale globally – NUSO’s international network enables consistent delivery of services across regions.
With these combined strengths, NUSO and Zoom are giving enterprises and resellers a more direct, reliable way to unify telephony, video, and contact center solutions while reducing complexity.
“The framework of a successful partnership always begins with a common goal - the customer,” said Nick Tidd, Head of Global Channel GTM at Zoom. “Zoom’s partnership with NUSO focuses on that customer experience by combining Zoom Phone and Zoom Contact Center technology with NUSO’s powerful global network. It also ensures our reseller partners have a more simplified way of delivering those customer experiences.”
The partnership will be announced at the Cavell Summit North America in Washington, D.C., where leaders in global cloud communications gather to showcase new approaches to enterprise collaboration.
Read more on NUSO.CLOUD.
About NUSO
NUSO enables partners and enterprises to deliver orchestrated, outcome-rich conversations at scale. NUSO unifies real-time AI, intelligent routing, and direct control of its global carrier network to power secure, scalable communications across unified communications, contact center, messaging, and customer engagement. The platform enhances network performance and customer experience through live transcription, sentiment analysis, and real-time automation. NUSO supports compliance and orchestration across voice provisioning, messaging, CX workflows, and call routing.
We Don’t Just Route Calls — We Orchestrate Outcomes.
NUSO is ISO 27001:2022 certified and operates across the United States, Canada, Latin America, UK, and EMEA. Learn more at www.nuso.cloud.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251006577741/en/
Contacts
Media Contact
Colleen Sheley
VP of Marketing, NUSO
marketing@nuso.cloud
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom